Results
Title

A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020.

Authors

Wada, Takehiko; Ishimoto, Takuji; Nakaya, Izaya; Kawaguchi, Takehiko; Sofue, Tadashi; Shimizu, Sayaka; Kurita, Noriaki; Sasaki, Sho; Nishiwaki, Hiroki; Koizumi, Masahiro; Saito, Shoji; Nishibori, Nobuhiro; Oe, Yuji; Yoshida, Mai; Miyaoka, Yoshitaka; Akiyama, Shin'ichi; Itano, Yuya; Okazaki, Masaki; Ozeki, Takaya; Ichikawa, Daisuke

Abstract

Treatment-resistant MN If the patient does not achieve complete remission or incomplete remission type I after 4 weeks of corticosteroid monotherapy, additional treatment should be considered. 2) Initial treatment Oral prednisolone is administered once daily, starting at 0.8-1 mg/kg/day (maximum 60 mg/day), for 2-4 weeks as the initial treatment for primary FSGS with nephrotic syndrome. Grades of recommendations: 1 - "We recommend" 2 - "We suggest" None Definitions, underlying diseases, pathophysiology Definitions/diagnosis Nephrotic syndrome is a clinical syndrome characterized by severe proteinuria and hypoproteinemia (or hypoalbuminemia). If the patient does not achieve complete remission or incomplete remission type I after 6 months of conservative therapy, consider switching to corticosteroid monotherapy or combination treatment with corticosteroids and immunosuppressive agents.

Subjects

NEPHROTIC syndrome; DYSLIPIDEMIA; ACUTE kidney failure; FOCAL segmental glomerulosclerosis

Publication

Clinical & Experimental Nephrology, 2021, Vol 25, Issue 12, p1277

ISSN

1342-1751

Publication type

Academic Journal

DOI

10.1007/s10157-021-02098-5